Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Sacubitril/valsartan real-world persistence using a cohort of heart failure patients from the PRescription & Monitoring of sacubitril/valsartan study (PRiMe 2 study)
Session:
Posters - D. Heart Failure
Speaker:
António Teixeira Rodrigues
Congress:
CPC 2021
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters
FP Number:
---
Authors:
António Teixeira Rodrigues; Rodrigo Murteira; Carolina Bulhosa; Maria Cary; José Pedro Guerreiro; Pedro Laires; Marta Afonso-Silva
Abstract
<p><strong>Objectives: </strong><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-size:10.0pt">The primary objective of this study was to characterize the real-world persistence of sacubitril/valsartan (sac/val) at 12 months.</span></span></span></p> <p><strong>Methods:</strong> <span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">This</span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif"> was a cross-sectional </span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">study of </span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">patients with a sac/val prescription </span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">originally identified in Portuguese community pharmacies using primary and secondary data collection. PRiMe study participants (</span></span><u><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">></span></span></u><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">18 years heart failure patients or caregivers) who</span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif"> gave their consent to participate in the follow-up PRiMe 2 study </span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif">answered a telephone-based questionnaire. Whenever it was unfeasible to reach patients, pharmacists were contacted to support with data collection. <span style="background-color:white"><span style="color:black">Persistence was measured as the proportion of patients continuing therapy with sac/val after 12 months. Functional status was measured through the self-assessed New York Heart Association (NYHA) questionnaire.</span></span></span></span></p> <p><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif"><span style="background-color:white"><span style="color:black"><strong>Results:</strong> </span></span>As of Aug 2020, amongst the 285 patients recruited for PRiMe, we were able to collect sac/val persistence data for 284 patients. The median age of patients was 72 years (IQR=63-80), 65.5% were male and the median follow-up was 19.6 months (IQR=14.8-23.9). The estimated persistence of sac/val at 12 months was 85.96% and varied across different sac/val initiating doses (p=0.22). In the majority of cases, sal/val discontinuation occurred in the first 180 days of treatment. Persistence at 12 months among patients <75 years was higher when compared to patients ≥75 years (p=0.0316).</span></span><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif"> After a median time of 16.6 months (IQR, 12.5-19.3) of sac/val treatment, 42.7% of patients improved their self-assessed NYHA while 48.5% did not report heart failure signs and symptoms’ progression and maintained their self-assessed NYHA. </span></span></p> <p><span style="font-size:10.0pt"><span style="font-family:"Arial",sans-serif"><strong>Conclusions:</strong> Our findings suggest that sac/val real-world persistence at 12 months was high and that heart failure patients on treatment with sac/val tend to improve their self-reported functional status.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site